Bionic Vision Restoration System BionicSight Receives FDA Approval: Retinal Chip Restores Low-Resolution Vision to Blind Patients

From Darkness to Blurry Light

On September 8, 2029, BionicVision Technologies announced that its bionic vision restoration system BionicSight received FDA approval. This represents the most important commercialization milestone in bionic vision technology since Second Sight Medical's bankruptcy in 2020.

BionicSight comprises three components: smart glasses with a miniature camera, a signal processing unit worn at the waist, and a microchip implanted on the retinal surface. Visual signals captured by the camera are converted to electrical impulses by the processing unit, wirelessly transmitted to drive a 1,024-microelectrode array on the retinal chip that stimulates retinal ganglion cells, bypassing damaged photoreceptors to deliver visual information directly to the brain.

The system restores 48x48 pixel (approximately 2,304 pixel) low-resolution vision. While this resolution is far below normal human vision's millions of pixels, for patients completely blind due to retinitis pigmentosa (RP) and similar conditions, it means regaining the ability to perceive light, recognize object outlines, and judge spatial orientation.

BionicVision CEO Robert Greenberg (also a Second Sight co-founder) said: "We spent 20 years proving one thing: even the crudest electronic vision is vastly better than complete darkness. BionicSight patients can walk independently, recognize family members' facial outlines, and even read large-print text."

Clinical Data

The pivotal trial enrolled 86 patients across 12 medical centers. At 6 months post-implantation, 92% could navigate indoor environments independently, 78% could identify common household objects, and 45% could recognize large-print text. The system is priced at $150,000 including surgical costs. BionicVision is negotiating CMS coverage, expecting a preliminary decision by Q1 2030.